ClinicalTrials.gg
CompletedNCT06156696Updated Sep 30, 2026Results posted

A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes Mellitus

An interventional study of BAP0527 and Blood Glucose Meter in Type 2 Diabetes Mellitus, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Astellas Pharma Inc · Interventional and Treatment

How we know

Updated Sep 30, 2026Now CompletedResults posted+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Astellas Pharma Inc.

Enrollment
6th of 32
248 · median 128
Started
2024
the only one that year
No phase
Only one
of the 35
Registered
35th of 35
by date

Among the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc, this one is the 6th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 35th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc as a file.
02

Study summary

The subjects of this study are patients with type 2 diabetes mellitus. The patients take part in dietetic therapy and exercise therapy, and also receive diabetes education to improve lifestyle habits, but since diet and exercise are lifestyle-based, it is generally difficult to make lifestyle changes and continue self-management for diabetes management.

The objective of this study is to determine whether the use of a diabetes treatment support system (BAP0527 and blood glucose meter, hereafter, this product) would allow type 2 diabetes mellitus patients to control their blood glucose well.

BAP0527 is a modified Japanese version of BlueStar®, a smartphone application approved by the U.S. Food and Drug Administration to manage and support the treatment of diabetes in adults. The blood glucose meter is a device that measures blood glucose levels from fingertips and palm blood using a dedicated paracentesis device (a device used to draw blood). In this study, BAP0527 will be used in conjunction with the blood glucose meter.

This study is open-label. Open-label means that subjects participating in this study are aware of whether they use this product in addition to their daily practice and treatment. Whether a subject uses this product or not is determined randomly. The subjects in the group using this product will be required to install BAP0527 on their smartphones and record their lifestyle habits (diet, exercise, sleep), medication compliance, blood pressure, pulse, weight, and also blood glucose levels measured by the blood glucose meter. In addition, they will review lifestyle habits according to the messages sent by BAP0527 based on the inputs, and watch educational contents. On the other hand, subjects in the group not using this product will continue to receive the treatment they have taken before participating in the study.

The study period is approximately 10 months. During this period, a subject will visit a hospital approximately 12 times. For subjects in the group who use this product, the duration of use of this product is approximately 6 months.

When a subject visits a hospital, a study doctor will confirm if the subject has a health problem. In addition, laboratory test, body temperature, blood pressure, and pulse will be confirmed. Blood/urine samples will be collected from subjects for laboratory tests.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • type 2 diabetes mellitus (T2DM)
  • BAP0527
  • Blood Glucose Meter
  • Diabetes treatment support system
  • Digital health product
  • Self-monitoring of blood glucose (SMBG)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has been diagnosed with type 2 diabetes for at least 12 weeks (84 days) at visit 1.
  • Participants being treated with only diet and exercise therapy, or participants being treated with hypoglycemics other than insulin preparations in addition to diet and exercise therapy, who have continued the same treatment for at least 12 weeks (84 days) as of visit 1.
  • Participants who have potential for improvement from self-management of diabetes mellitus, including diet therapy and exercise therapy, and who are willing to improve their self-management of diabetes mellitus, while complying with the rules for participants relating to the use of BAP0527 and the blood glucose meter, as of visit 1.
  • Participants who are able to perform outpatient management while participating in this study, as of visit 1.
  • Participants have no problems inputting information into BAP0527 or using the blood glucose meter, from the perspective of cognitive function, visual acuity or device operating ability, as of visit 1.
  • Participants having and using a smartphone device meeting the following operating system requirements as of visit 1

    • For iOS: Version 13 or later
    • For Android: Version 10 or later
  • Participants with an level >/=8.0% and \</=10.0% (central lab measurement) as of visit 1.
  • Participants who also meet inclusion criteria from the second to the sixth at visit 2.
  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a Woman of (WOCBP)
    • A WOCBP who has a negative urine or serum pregnancy test between the time of providing and visit 2 and agrees to follow the guidance from the time of informed consent through the end of the follow-up period.
  • Female participant is consenting not to breastfeed from the time of providing informed consent until the end of the follow-up period.
  • Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed with a type of diabetes mellitus other than type 2 diabetes mellitus, such as type 1 diabetes mellitus or secondary diabetes mellitus.
  • Participants with a history of, or currently receiving treatment for, diabetic ketoacidosis.
  • Participants with retinopathy proliferative (however, if treatment such as photocoagulation has been performed and symptoms are stable, the participant may be enrolled).
  • Participants diagnosed with clinically problematic cardiovascular or cerebrovascular disease such as myocardial infarction, poorly controlled angina pectoris/coronary artery disease, clinically problematic ventricular arrhythmia, cardiac failure (class III or IV according to the classification) in the period of 12 weeks (84 days) before visit 1 (including the date of visit 1).
  • Participants with chronic disease requiring continuous use (such as oral use or injection) of adrenocortical or for their systemic action.
  • Participants with a concurrent malignant tumor (with a relapse-free period of less than 5 years).
  • Participants with concurrent serious infection.
  • Participants with concurrent serious hepatic disorder.
  • Participants with drug addiction, alcohol dependence or unstable psychiatric disease.
  • Participants using insulin preparations.
  • Participants who plan to be hospitalized or receive surgery during the period of participants in this study.
  • Participants who have already been assigned in this study.
  • Participants who receive any study treatment (including a follow-up period) in the period of 12 weeks (84 days) before visit 1 (including the date of visit 1) or who participate in any study treatment, when 5 half-lives of this treatment have not elapsed as of 12 weeks (84 days) before visit 1.
  • Participants who have used a mobile application operating on a smartphone device for managing, or assisting in the management of, diabetes mellitus in the 12 weeks (84 days) before visit 1 (including the date of visit 1), when judged that the possibility of this history of use affecting efficacy evaluation in this study cannot be ruled out.
  • Participants with a difference of more than 1.0% in the maximum and minimum levels (measured at the hospital) measured in the 12 weeks (84 days) before visit 1 (including the date of visit 1).
  • Participants with systolic blood pressure (SBP) >180 mmHg or diastolic blood pressure (DBP) >110 mmHg at rest in a sitting position at either visit 1, visit 2 or both or participants with SBP>160 mmHg or DBP >100 mmHg at rest in a sitting position at both visit 1 and visit 2.
  • Participants with concurrent diabetic nephropathy of stage 3 or higher (estimated glomerular filtration rate [] \< 30 mL/min/1.73m\^2 or urinary albumin >/= 300 mg/gCre [each centrally measured values at visit 1]).
  • Participants who have and use a smartphone device on which BAP0527 may not be displayed appropriately, or who plan to buy a new smartphone device on which BAP0527 may not be displayed appropriately between the time of providing and the end of the treatment period.
  • Participants who are employees of Astellas Group, Welldoc, Inc., Roche DC Japan K.K. or a study site, or the CRO involved in the study.
  • Participant has any condition, which makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    BAP0527 group

    Participants use the BAP0527 and Blood Glucose Meter in addition to the usual treatment at each site.

    Device: BAP0527 · Device: Blood Glucose Meter

  • No intervention
    Usual treatment group

    Participants receive the usual treatment they received before participating in the study.

Interventions

  • DeviceBAP0527

    Participants will continuously use BAP0527, while measuring their daily blood glucose levels using the blood glucose meter, and will input daily self-management records such as lifestyle habits (diet, exercise, sleep), use of medication and measurements (blood glucose level, blood pressure, pulse rate, body weight) into BAP0527.

  • DeviceBlood Glucose Meter

    Participants measure blood glucose using a blood glucose meter in daily life.

    Also known as: ACCU-CHEK® Guide Me

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c Level at Week 24

    The change from Baseline in HbA1c level at Week 24 (central lab measurement) was defined by the formula: HbA1c level at Week 24 - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were missing at random (MAR).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in HbA1c Level at Each Assessment Timepoint (Except Week 24)

    The change from Baseline in HbA1c level at each assessment time point (except Week 24) (central lab measurement) was defined by the formula: HbA1c level at each assessment time point (Weeks 4 to 20) - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (except Week 24) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

    Time frame: Baseline and Weeks 4, 8, 12, 16, and 20

  2. Percentage of Participants With a Baseline HbA1c Level ≥ 8.0% Who Achieved an HbA1c Level < 8.0% at Week 24

    The percentage of participants with a Baseline HbA1c level ≥ 8.0% who achieved an HbA1c level \< 8.0% at Week 24 (central lab measurement) was defined by the formula: (number of participants with an HbA1c level ≥ 8.0% at Baseline and an HbA1c level \< 8.0% at Week 24) / (Number of participants with an HbA1c level ≥ 8.0% at Baseline). If the HbA1c level at Week 24 was missing, the imputed HbA1c level under the assumption of MAR was used.

    Time frame: Week 24

  3. Change From Baseline Value in Fasting Blood Glucose Level at Week 24

    The change from Baseline in fasting blood glucose level at Week 24 (central lab measurement) was defined by the formula: fasting blood glucose level at Week 24 - fasting blood glucose level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting blood glucose level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

    Time frame: Baseline and Week 24

  4. Change From Baseline Value in Fasting Insulin Level at Week 24

    The change from Baseline in fasting insulin level at Week 24 (central lab measurement) was defined by the formula: fasting insulin level at Week 24 - fasting insulin level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting insulin level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

    Time frame: Baseline and Week 24

  5. Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 24, Relative to Antidiabetic Use at Baseline

    The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants who use antidiabetics at Baseline and then have a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24 relative to antidiabetic use at Baseline) / (number of participants who use antidiabetics at Baseline). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics is decreased or the number of antidiabetics is reduced at least once by Week 24 compared with the dose or number of antidiabetics at Baseline.

    Time frame: Baseline up to Week 24

  6. Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 24, Relative to Antidiabetic Use at Baseline

    The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants in the FAS with an increased dose of antidiabetics or newly started hypoglycemics by Week 24 relative to antidiabetic use at Baseline) / (number of participants in the FAS). An increased dose of antidiabetics or newly started hypoglycemics was defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once by Week 24 compared with the dose of antidiabetics or the number of hypoglycemics at Baseline.

    Time frame: Baseline up to Week 24

  7. Change From Baseline in HbA1c Level in the Follow-up Period

    The change from Baseline in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

    Time frame: Baseline and Weeks 28, 32 and 36

  8. Change From Week 24 in HbA1c Level in the Follow-up Period

    The change from Week 24 in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Week 24. A negative change indicates a reduction/improvement from Week 24 (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

    Time frame: Week 24 and Weeks 28, 32 and 36

  9. Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24

    The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (number of participants who start the follow-up, use antidiabetics at Week 24, and have a decreased dose of antidiabetics or reduced number of antidiabetics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (number of participants who start the follow-up and use antidiabetics at Week 24). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics was decreased or the number of antidiabetics was reduced at least once between Week 28 and Week 36 compared with the dose or number of antidiabetics at Week 24.

    Time frame: Week 24 up to Week 36

  10. Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24

    The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (Number of participants in the FAS2 with an increased dose of antidiabetics or newly started hypoglycemics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (Number of participants in the FAS2). An increased dose of antidiabetics or newly started hypoglycemics is defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once between Week 28 and Week 36 compared with the dose of antidiabetics or the number of hypoglycemics at Week 24.

    Time frame: Week 24 up to Week 36

  11. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient, clinical study participant, user or other person, temporally associated with the use of study intervention, whether or not considered related to the study intervention. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the device used in the clinical study, if applicable, and events related to the (study) procedures. A device-related AE is an AE that is related to the use of a device used in the clinical study. This includes AEs caused by an omission in the instruction manual for the use, dispensing or operation of a device used in the clinical study, or a deficiency in the device used in the clinical study. It also includes AEs occurring due to the improper use (including intentional improper use) of a device used in the clinical study.

    Time frame: From Day 1 up to Week 36

  12. Number of Participants Who Experienced Device Deficiency

    A deficiency in a device is the situation where a device used in the clinical study is broadly in a poor condition in relation to quality, safety or performance, such as device damage or malfunctions, regardless of whether this occurs at the stage of design, dispensing, storage or use.

    Time frame: From Day 1 up to Week 24

07

Results

Posted Sep 30, 2026

Participant flow

Participants of either gender, of at least 18 years old of age, with the diagnosis of type 2 diabetes mellitus were enrolled in this study.

Treatment Period
Participant flow — Treatment Period
MilestoneUsual Treatment GroupBAP0527 Group
Started125123
Completed122121
Not completed32
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Withdrew: Physician decision10
Withdrew: Protocol deviation11
Follow-up Period
Participant flow — Follow-up Period
MilestoneUsual Treatment GroupBAP0527 Group
Started122121
Completed122117
Not completed04
Withdrew: Death01
Withdrew: Withdrawal by subject01
Withdrew: Protocol deviation02

Outcome measures

PrimaryChange From Baseline in HbA1c Level at Week 24

The change from Baseline in HbA1c level at Week 24 (central lab measurement) was defined by the formula: HbA1c level at Week 24 - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were missing at random (MAR).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · change in HbA1c percentage
Change From Baseline in HbA1c Level at Week 24
change in HbA1c percentageUsual Treatment GroupBAP0527 Group
Change From Baseline in HbA1c Level at Week 24-0.38 ± 0.08-0.49 ± 0.08
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.330 · Difference in ls mean: -0.11 · 95% CI -0.32 to 0.11If the HbA1c level at Week 24 was missing, this analysis was conducted under the assumption of MAR.
SecondaryChange From Baseline in HbA1c Level at Each Assessment Timepoint (Except Week 24)

The change from Baseline in HbA1c level at each assessment time point (except Week 24) (central lab measurement) was defined by the formula: HbA1c level at each assessment time point (Weeks 4 to 20) - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (except Week 24) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

Time frame:
Baseline and Weeks 4, 8, 12, 16, and 20
Reported as:
Least squares mean · change in HbA1c percentage
Change From Baseline in HbA1c Level at Each Assessment Timepoint (Except Week 24)
change in HbA1c percentageUsual Treatment GroupBAP0527 Group
Week 4-0.06 ± 0.03-0.26 ± 0.03
Week 8-0.13 ± 0.05-0.36 ± 0.05
Week 12-0.21 ± 0.07-0.44 ± 0.07
Week 16-0.22 ± 0.07-0.47 ± 0.07
Week 20-0.31 ± 0.08-0.46 ± 0.08
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = <0.001 · Difference in ls mean: -0.20 · 95% CI -0.29 to -0.10If the HbA1c level at Week 4 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.003 · Difference in ls mean: -0.22 · 95% CI -0.37 to -0.07If the HbA1c level at Week 8 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.013 · Difference in ls mean: -0.23 · 95% CI -0.41 to -0.05If the HbA1c level at Week 12 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.013 · Difference in ls mean: -0.25 · 95% CI -0.45 to -0.05If the HbA1c level at Week 16 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.163 · Difference in ls mean: -0.15 · 95% CI -0.36 to 0.06If the HbA1c level at Week 20 was missing, this analysis was conducted under the assumption of MAR.
SecondaryPercentage of Participants With a Baseline HbA1c Level ≥ 8.0% Who Achieved an HbA1c Level < 8.0% at Week 24

The percentage of participants with a Baseline HbA1c level ≥ 8.0% who achieved an HbA1c level \< 8.0% at Week 24 (central lab measurement) was defined by the formula: (number of participants with an HbA1c level ≥ 8.0% at Baseline and an HbA1c level \< 8.0% at Week 24) / (Number of participants with an HbA1c level ≥ 8.0% at Baseline). If the HbA1c level at Week 24 was missing, the imputed HbA1c level under the assumption of MAR was used.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Baseline HbA1c Level ≥ 8.0% Who Achieved an HbA1c Level < 8.0% at Week 24
percentage of participantsUsual Treatment GroupBAP0527 Group
Percentage of Participants With a Baseline HbA1c Level ≥ 8.0% Who Achieved an HbA1c Level < 8.0% at Week 2433.542.0
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Odds ratio (or): 1.4 · 95% CI 0.83 to 2.43
SecondaryChange From Baseline Value in Fasting Blood Glucose Level at Week 24

The change from Baseline in fasting blood glucose level at Week 24 (central lab measurement) was defined by the formula: fasting blood glucose level at Week 24 - fasting blood glucose level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting blood glucose level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline Value in Fasting Blood Glucose Level at Week 24
mg/dLUsual Treatment GroupBAP0527 Group
Change From Baseline Value in Fasting Blood Glucose Level at Week 24-17.1 ± 3.9-17.7 ± 3.9
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Difference in ls mean: -0.6 · 95% CI -11.5 to 10.3
SecondaryChange From Baseline Value in Fasting Insulin Level at Week 24

The change from Baseline in fasting insulin level at Week 24 (central lab measurement) was defined by the formula: fasting insulin level at Week 24 - fasting insulin level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting insulin level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · uIU/mL
Change From Baseline Value in Fasting Insulin Level at Week 24
uIU/mLUsual Treatment GroupBAP0527 Group
Change From Baseline Value in Fasting Insulin Level at Week 240.068 ± 0.7640.270 ± 0.763
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Difference in ls mean: 0.202 · 95% CI -1.924 to 2.329
SecondaryPercentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 24, Relative to Antidiabetic Use at Baseline

The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants who use antidiabetics at Baseline and then have a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24 relative to antidiabetic use at Baseline) / (number of participants who use antidiabetics at Baseline). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics is decreased or the number of antidiabetics is reduced at least once by Week 24 compared with the dose or number of antidiabetics at Baseline.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 24, Relative to Antidiabetic Use at Baseline
percentage of participantsUsual Treatment GroupBAP0527 Group
Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 24, Relative to Antidiabetic Use at Baseline13.715.8
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Odds ratio (or): 1.2 · 95% CI 0.60 to 2.54
SecondaryPercentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 24, Relative to Antidiabetic Use at Baseline

The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants in the FAS with an increased dose of antidiabetics or newly started hypoglycemics by Week 24 relative to antidiabetic use at Baseline) / (number of participants in the FAS). An increased dose of antidiabetics or newly started hypoglycemics was defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once by Week 24 compared with the dose of antidiabetics or the number of hypoglycemics at Baseline.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 24, Relative to Antidiabetic Use at Baseline
percentage of participantsUsual Treatment GroupBAP0527 Group
Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 24, Relative to Antidiabetic Use at Baseline40.829.3
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Odds ratio (or): 0.6 · 95% CI 0.33 to 0.97
SecondaryChange From Baseline in HbA1c Level in the Follow-up Period

The change from Baseline in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

Time frame:
Baseline and Weeks 28, 32 and 36
Reported as:
Least squares mean · change in HbA1c percentage
Change From Baseline in HbA1c Level in the Follow-up Period
change in HbA1c percentageUsual Treatment GroupBAP0527 Group
Week 28-0.42 ± 0.08-0.39 ± 0.08
Week 32-0.41 ± 0.08-0.29 ± 0.08
Week 36-0.37 ± 0.08-0.27 ± 0.09
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.730 · Difference in ls mean: 0.04 · 95% CI -0.18 to 0.26If the HbA1c level at Week 28 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.323 · Difference in ls mean: 0.12 · 95% CI -0.11 to 0.35If the HbA1c level at Week 32 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.412 · Difference in ls mean: 0.10 · 95% CI -0.14 to 0.34If the HbA1c level at Week 36 was missing, this analysis was conducted under the assumption of MAR.
SecondaryChange From Week 24 in HbA1c Level in the Follow-up Period

The change from Week 24 in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Week 24. A negative change indicates a reduction/improvement from Week 24 (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.

Time frame:
Week 24 and Weeks 28, 32 and 36
Reported as:
Least squares mean · change in HbA1c percentage
Change From Week 24 in HbA1c Level in the Follow-up Period
change in HbA1c percentageUsual Treatment GroupBAP0527 Group
Week 28-0.04 ± 0.030.07 ± 0.03
Week 32-0.02 ± 0.050.17 ± 0.05
Week 360.02 ± 0.060.19 ± 0.07
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.024 · Difference in ls mean: 0.11 · 95% CI 0.01 to 0.20If the HbA1c level at Week 28 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.012 · Difference in ls mean: 0.19 · 95% CI 0.04 to 0.33If the HbA1c level at Week 32 was missing, this analysis was conducted under the assumption of MAR.
  • Usual Treatment Group vs BAP0527 Group · Mixed Models Analysis · p = 0.064 · Difference in ls mean: 0.17 · 95% CI -0.01 to 0.36If the HbA1c level at Week 36 was missing, this analysis was conducted under the assumption of MAR.
SecondaryPercentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24

The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (number of participants who start the follow-up, use antidiabetics at Week 24, and have a decreased dose of antidiabetics or reduced number of antidiabetics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (number of participants who start the follow-up and use antidiabetics at Week 24). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics was decreased or the number of antidiabetics was reduced at least once between Week 28 and Week 36 compared with the dose or number of antidiabetics at Week 24.

Time frame:
Week 24 up to Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24
percentage of participantsUsual Treatment GroupBAP0527 Group
Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 248.54.2
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Odds ratio (or): 0.5 · 95% CI 0.16 to 1.48
SecondaryPercentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24

The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (Number of participants in the FAS2 with an increased dose of antidiabetics or newly started hypoglycemics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (Number of participants in the FAS2). An increased dose of antidiabetics or newly started hypoglycemics is defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once between Week 28 and Week 36 compared with the dose of antidiabetics or the number of hypoglycemics at Week 24.

Time frame:
Week 24 up to Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24
percentage of participantsUsual Treatment GroupBAP0527 Group
Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 2417.210.8
Statistical analysis
  • Usual Treatment Group vs BAP0527 Group · Odds ratio (or): 0.6 · 95% CI 0.28 to 1.24
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a patient, clinical study participant, user or other person, temporally associated with the use of study intervention, whether or not considered related to the study intervention. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the device used in the clinical study, if applicable, and events related to the (study) procedures. A device-related AE is an AE that is related to the use of a device used in the clinical study. This includes AEs caused by an omission in the instruction manual for the use, dispensing or operation of a device used in the clinical study, or a deficiency in the device used in the clinical study. It also includes AEs occurring due to the improper use (including intentional improper use) of a device used in the clinical study.

Time frame:
From Day 1 up to Week 36
Reported as:
Number · count of participants
Number of Participants With Adverse Events (AEs)
count of participantsUsual Treatment GroupBAP0527 Group
Number of Participants With Adverse Events (AEs)9995
SecondaryNumber of Participants Who Experienced Device Deficiency

A deficiency in a device is the situation where a device used in the clinical study is broadly in a poor condition in relation to quality, safety or performance, such as device damage or malfunctions, regardless of whether this occurs at the stage of design, dispensing, storage or use.

Time frame:
From Day 1 up to Week 24
Reported as:
Number · count of participants
Number of Participants Who Experienced Device Deficiency
count of participantsUsual Treatment GroupBAP0527 Group
Number of Participants Who Experienced Device Deficiency—31

Adverse events

Collected over All-cause mortality (ACM): From randomization up to 36 weeks Serious Adverse events (SAEs) and non-SAEs: From first dose up to 36 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period: Usual Treatment Group0/125 (0%)5/125 (4%)33/125 (26.4%)
Treatment Period: BAP0527 Group0/123 (0%)4/123 (3.3%)32/123 (26%)
Follow-up Period: Usual Treatment Group0/122 (0%)0/122 (0%)26/122 (21.3%)
Follow-up Period: BAP0527 Group1/121 (0.8%)2/121 (1.7%)15/121 (12.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTreatment Period: Usual Treatment GroupTreatment Period: BAP0527 GroupFollow-up Period: Usual Treatment GroupFollow-up Period: BAP0527 Group
DeathGeneral disorders0/1250/1230/1221/121
PyelonephritisInfections and infestations0/1250/1230/1221/121
Eyelid ptosisEye disorders0/1251/1230/1220/121
Humerus fractureInjury, poisoning and procedural complications0/1251/1230/1220/121
Subdural haematomaInjury, poisoning and procedural complications0/1251/1230/1220/121
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1251/1230/1220/121
InfluenzaInfections and infestations1/1250/1230/1220/121
PneumoniaInfections and infestations1/1250/1230/1220/121
Cervical vertebral fractureInjury, poisoning and procedural complications1/1250/1230/1220/121
Foot fractureInjury, poisoning and procedural complications1/1250/1230/1220/121
Most frequent other events
Most frequent other events
EventTreatment Period: Usual Treatment GroupTreatment Period: BAP0527 GroupFollow-up Period: Usual Treatment GroupFollow-up Period: BAP0527 Group
NasopharyngitisInfections and infestations26/12524/12318/12213/121
InfluenzaInfections and infestations4/1257/1235/1221/121
DiarrhoeaGastrointestinal disorders7/1254/1234/1222/121

Baseline characteristics

Randomized Analysis Set included all participants who completed screening and were randomized. Participants were analyzed according to the treatment group to which they were randomized.

Age, Continuous
Age, Continuous(Years)Usual Treatment GroupBAP0527 GroupTotal
Mean55.9 ± 11.256.3 ± 10.556.1 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Usual Treatment GroupBAP0527 GroupTotal
Female363672
Male8987176
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Usual Treatment GroupBAP0527 GroupTotal
Hispanic or Latino000
Not Hispanic or Latino125123248
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Usual Treatment GroupBAP0527 GroupTotal
American Indian or Alaska Native000
Asian125123248
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(Participants)Usual Treatment GroupBAP0527 GroupTotal
<25 kg/m^2464591
>=25 kg/m^27978157
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(HbA1c percentage)Usual Treatment GroupBAP0527 GroupTotal
Mean8.53 ± 0.598.60 ± 0.578.56 ± 0.58
08

Study locations

1 site
  • Shiraiwa medical clinic
    Kashiwara-shi, Osaka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2025, 16 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion. A results delay was requested in Jun 2026.

Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 16 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2023
First posted
Dec 5, 2023
StartActual
Feb 16, 2024
Primary completionActual
Jul 2, 2025
CompletionActual
Sep 10, 2025
Results delay requested
Jun 30, 2026
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Withheld→Completed
changed Sep 30, 2026
Results
Results posted
posted Sep 30, 2026
Sites
1 site added — first site in Japan
Show site
  • Shiraiwa medical clinic · Kashiwara-shi, Japan
Sep 30, 2026
Start date
Set to Feb 16, 2024 (actual)
Sep 30, 2026
Primary completion
Set to Jul 2, 2025 (actual)
Sep 30, 2026
Study completion
Set to Sep 10, 2025 (actual)
Sep 30, 2026
Eligibility
Revised
Sep 30, 2026
Interventions
Arms or interventions changed
Sep 30, 2026
Documents
Title
[Trial of device that is not approved or cleared by the U.S. FDA]→A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes Mellitus
Sep 30, 2026
Sponsor
[Redacted]→Astellas Pharma Inc
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Withheld→Completed
    Results posted
    1 site added — first site in Japan
    Show site
    • Shiraiwa medical clinic · Kashiwara-shi, Japan
    Start date Set to Feb 16, 2024 (now actual)
    Primary completion Set to Jul 2, 2025 (now actual)
    Study completion Set to Sep 10, 2025 (now actual)
    Eligibility Revised
    Interventions Arms or interventions changed
    Sponsor [Redacted]→Astellas Pharma Inc
    Title [Trial of device that is not approved or cleared by the U.S. FDA]→A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes Mellitus
    + 9 other changes: registry dates, verification date, oversight details, description, conditions, design details, secondary outcomes, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06156696
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Feb 16, 2024
Primary completion
Jul 2, 2025
Completion
Sep 10, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion